Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9

BMC Endocrine Disorders

Didac Mauricio¹  Alberto de Leiva⁷  Paolo Pozzilli⁶  Manel Puig-Domingo⁴  Ismael Capel⁷  Aureli Esquerda²  Josep Ramon Marsal⁵  Angels Mollo³  Marta Hernandez¹ 

[1] Institut de Recerca Biomedica de Lleida, Universitat de Lleida, Lleida, Spain;Clinical Laboratory, Hospital Universitari Arnau de Vilanova, Lleida, Spain;Centre d’Atenció Primària de Cervera, Institut Català de la Salut, Lleida, Spain;Department of Endocrinology and Nutrition, Hospital Univesitari Germans Trias i Pujol, Carretera Canyet, S/N, 08916 Badalona, Spain;Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain;Centre of Diabetes, Barts and the London School of Medicine, Queen Mary University of London, London, UK;CIBER de Bioingeniería, Biomateriales y Nanomedicina, Barcelona, Spain

关键词: C-peptide;    Insulin secretion;    Type 2 diabetes mellitus;    Type 1 diabetes mellitus;    Latent autoimmune diabetes in adults;   

Others  :  1084650
DOI  :  10.1186/1472-6823-15-1

 received in 2014-03-09, accepted in 2015-01-05,  发布年份 2015

【 摘 要 】

Background

The study of endogenous insulin secretion may provide relevant insight into the comparison of the natural history of adult onset latent autoimmune diabetes (LADA) with types 1 and 2 diabetes mellitus. The aim of this study was to compare the results of the C-peptide response to mixed-meal stimulation in LADA patients with different disease durations and subjects with type 2 and adult-onset type 1 diabetes.

Methods

Stimulated C-peptide secretion was assessed using the mixed-meal tolerance test in patients with LADA (n = 32), type 1 diabetes mellitus (n = 33) and type 2 diabetes mellitus (n = 30). All patients were 30 to 70 years old at disease onset. The duration of diabetes in all groups ranged from 6 months to 10 years. The recruitment strategy was predefined to include at least 10 subjects in the following 3 disease onset categories for each group: 6 to 18 months, 19 months to 5 years and 5 to 10 years.

Results

At all time-points of the mixed-meal tolerance test, patients with LADA had a lower stimulated C-peptide response than the type 2 diabetes group and a higher response than the type 1 diabetes group. The same results were found when the peak or area under the C-peptide curve was measured. When the results were stratified by time since disease onset, a similar pattern of residual insulin secretory capacity was observed.

Conclusions

The present study shows that the magnitude of stimulated insulin secretion in LADA is intermediate between that of type 1 and type 2 diabetes mellitus.

【 授权许可】

   
2015 Hernandez et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Stenström G, Gottsätter A, Bakhtadze E, Berger B, Sundkvist G: Latent autoimmune diabetes in adults. Definition, prevalence, β-cell function, and treatment. Diabetes 2005, 54(Suppl2):S68-72.
• [2]Carlsson A, Sundqvist G, Groop L, Tuomi T: Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000, 85:76-80.
• [3]Hosszúfalusi N, Vatay A, Rajczy K, Prohászka Z, Pozsonyi E, Horváth L, et al.: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003, 26:452-7.
• [4]Yang L, Zhou Z-G, Huang G, Ouyang L-L, Li X, Yan X: Six-year follow-up of pancreatic β-cell function in adults with latent autoimmune diabetes. World J Gastroenterol 2005, 11:2900-5.
• [5]Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, et al.: Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control. Diabetes Metab 2010, 36:64-70. doi:10.1016/j.diabet.2009.07.004
• [6]Lee SA, Lee WJ, Kim EH, Yu JH, Jung CH, Koh EH, et al.: Progression to insulin deficiency in Korean patients with type 2 diabetes mellitus positive for anti-GAD antibody. Diabet Med 2011, 28:319-24. doi:10.1111/j.1464-5491.2010.03186.x
• [7]Thunander M, Thorgeirsson H, Törn C, Petersson C, Landin-Olsson M: ß-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011, 164:239-45. doi:10.1530/EJE-10-0901
• [8]Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, et al.: Latent autoimmune diabetes (LADA) is perched between type 1 and type 2: evidence from adults in one region of Spain. Diab Metab Res Rev 2013, 29:693. doi:10.1002/dmrr.2411
• [9]Greenbaum CJ, Harrison LC: Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003, 52:1059-65.
• [10]Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, et al.: Time to insulin initiation cannot be used in defining latent autoimmune diabetes of the adult. Diabetes Care 2008, 31:439-41.
• [11]Palomer X, Mauricio D, Rodríguez-Espinosa J, Zapico E, Mayoral C, González-Sastre F, et al.: Evaluation of two nonisotopic immunoassays for determination of glutamic acid decarboxylase and tyrosine phosphatase autoantibodies in serum. Clin Chem 2004, 50:1378-82.
• [12]Chen S, Willis J, Maclean C, Ananieva-Jordanova R, Amoroso MA, Brooking H, et al.: Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65. Cin Chim Acta 2005, 357:74-83.
• [13]Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, et al.: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008, 31:1966-71.